Exelon News and Research

RSS

Rivastigmine (sold under the trade name Exelon) is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer’s type and dementia due to Parkinson's disease. Side effects may include nausea and vomiting. Administration with a transdermal patch has fewer side effects compared to oral. Elimination is through the urine. It has likely relatively few drug-drug interactions.

GEH, Exelon Generation agree to a landmark deal to deploy GEH’s isotope generation technology

Seeking to address a growing demand for the domestic and global supply of cobalt-60, a radioisotope used for treating cancer and other biomedical applications, GE Hitachi Nuclear Energy (GEH) and Exelon Generation Company have agreed to a landmark deal to deploy GEH’s isotope generation technology.

20 Jan 2010

Philadelphia coalition calls on U.S. Chamber President to end his campaign against health care reform

The President of the U.S. Chamber of Commerce was greeted in Philadelphia today by a coalition demanding that he end his campaign against health care and clean energy reform.

31 Oct 2009

Bradycardia more likely in patients taking cholinesterase inhibitors

People taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications.

3 Oct 2009

Dementia drugs Aricept, Exelon and Reminyl may put some patients at risk

Side effects associated with several commonly-prescribed dementia drugs may be putting elderly Canadians at risk, says Queen's University Geriatrics professor Sudeep Gill.

27 May 2009

Dual treatment of incontinence and dementia associated with functional decline

Older nursing home residents who took medications for dementia and incontinence at the same time had a 50 percent faster decline in function than those who were being treated only for dementia, according to a study from researchers at Wake Forest University School of Medicine and colleagues.

1 May 2008

Dual treatment of incontinence and dementia associated with functional decline

30 Apr 2008

New drug may restore memory with Alzheimer's disease

A 2006 study by MetLife found that adults over age 55 fear Alzheimer's disease more than cancer, and with good reason. Alzheimer's creeps up on patients and their families, robbing more than half of all Americans over age 85 of their memory and ability to care for themselves.

14 Nov 2007

New skin patch treatment for Alzheimer's approved by the European Commission

A skin patch to treat Alzheimer's disease has been approved by the European Commission.

25 Sep 2007

FDA tells drug giant to come clean about Alzheimer's drug

The Food and Drug Administration (FDA) in the U.S. has warned a major drug company about misleading the medical profession over a drug for dementia.

15 Aug 2007

New skin patch offers help for Alzheimer's victims

The Food and Drug Administration (FDA) in the United States has given approval for the first skin patch to treat Alzheimer's disease.

9 Jul 2007

Furore over who gets Alzheimer's drug in the UK

A furore has erupted in Britain over a decision by the National Institute for Clinical Excellence (NICE), not to recommend the use of an Alzheimer's drug for newly diagnosed patients.

20 Nov 2006

Brits unable to access Alzheimer's drugs

It appears that people in Britain suffering from Alzheimer's disease will be unlikely to benefit from the use of four drugs designed to treat the the degenerative brain disease.

16 Oct 2006

New 'patch' drug therapy for Alzheimer's has fewer side effects

Alzheimer's, is the most common form of dementia and affects as many as 15 million people worldwide.

20 Jul 2006

FDA approves Exelon to treat dementia of Parkinson's disease

FDA approves Exelon (rivastigmine tartrate) for the treatment of mild to moderate dementia associated with Parkinson's disease.

27 Jun 2006

Aricept, Razadyne and Exelon can help people with mild Alzheimer's

The Alzheimer's drugs Aricept, Razadyne and Exelon can lead to small improvements in mental functioning and the ability to carry out everyday activities in people with mild to moderate forms of the disease, according to a new review of recent studies.

25 Jan 2006

Concern over decision that new Alzheimer drugs only available for advanced disease

The recommendation by the National Institute of Clinical Evidence (NICE), that Alzheimer's drugs should be used in a minority of people with the degenerative brain disease, has created both rage and disbelief from charities and drug companies alike.

24 Jan 2006

UK medical watchdog wants more proof on value of Alzheimer's drugs

In the UK the country's watchdog for cost-effectiveness in medical treatments, the National Institute for Health and Clinical Excellence (NICE), has asked drug makers for more evidence about the benefits of their Alzheimer's medicines.

21 Jul 2005

Decision to cut Alzheimer's drugs challenged

Four major drugs, the only drugs licensed in Britain for the treatment of Alzheimer's disease and available on the NHS may be withdrawn. Aricept, Exelon, Reminyl and Ebixa are the only drugs licensed in Britain for the treatment of the disease.

14 Mar 2005

Trial of new type of drug that attacks amyloid

Neuroscientists at the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia will begin a clinical trial testing a new type of drug that attacks amyloid, the protein substance that accumulates in the brains of Alzheimer’s disease patients.

4 Nov 2004

Warning on Alzheimer drug mix up

Janssen Pharmaceutica, manufacturer of the Alzheimer drug galantamine (Reminyl), says it has learned of 10 cases in which individuals who should have gotten Reminyl accidentally received the diabetes drug glimepiride (Amaryl).

1 Nov 2004